DUPHALAC (lactulose), hypoammonaemic osmotic laxative
GASTRO-ENTEROLOGY - Update
Opinions on drugs -
Posted on
Jun 27 2018
Reason for request
Renewal of inclusion
Moderate clinical benefit for hepatic encephalopathy and constipation
-
DUPHALAC has been granted a marketing authorisation for hepatic encephalopathy and for the symptomatic treatment of constipation.
-
In cases of constipation, it should only be envisaged after lifestyle and dietary measures have failed and in combination with such measures.
-
In cases of hepatic encephalopathy, it is recommended in cases of minimal or subclinical encephalopathy as a first-line symptomatic treatment in the acute phase, supplementing triggering factor management, and for preventing recurrences, with a non-optimal level of evidence.
Clinical Benefit
Moderate |
- |
English version
Contact Us
Évaluation des médicaments